warfarin has been researched along with Pseudoxanthoma-Elasticum* in 2 studies
2 other study(ies) available for warfarin and Pseudoxanthoma-Elasticum
Article | Year |
---|---|
Vitamin K reduces hypermineralisation in zebrafish models of PXE and GACI.
The mineralisation disorder pseudoxanthoma elasticum (PXE) is associated with mutations in the transporter protein ABCC6. Patients with PXE suffer from calcified lesions in the skin, eyes and vasculature, and PXE is related to a more severe vascular calcification syndrome called generalised arterial calcification of infancy (GACI). Mutations in ABCC6 are linked to reduced levels of circulating vitamin K. Here, we describe a mutation in the zebrafish (Danio rerio) orthologue abcc6a, which results in extensive hypermineralisation of the axial skeleton. Administration of vitamin K to embryos was sufficient to restore normal levels of mineralisation. Vitamin K also reduced ectopic mineralisation in a zebrafish model of GACI, and warfarin exacerbated the mineralisation phenotype in both mutant lines. These data suggest that vitamin K could be a beneficial treatment for human patients with PXE or GACI. Additionally, we found that abcc6a is strongly expressed at the site of mineralisation rather than the liver, as it is in mammals, which has significant implications for our understanding of the function of ABCC6. Topics: Animals; Anthraquinones; ATP-Binding Cassette Transporters; Calcinosis; Chromosomes, Artificial, Bacterial; DNA Primers; In Situ Hybridization; Mutation; Pseudoxanthoma Elasticum; Transgenes; Vascular Calcification; Vitamin K; Warfarin; Zebrafish; Zebrafish Proteins | 2015 |
Warfarin accelerates ectopic mineralization in Abcc6(-/-) mice: clinical relevance to pseudoxanthoma elasticum.
Pseudoxanthoma elasticum (PXE) is a multisystem ectopic mineralization disorder caused by mutations in the ABCC6 gene. Warfarin, a commonly used anticoagulant, is associated with increased mineralization of the arterial blood vessels and cardiac valves. We hypothesized that warfarin may accelerate ectopic tissue mineralization in PXE, with clinical consequences. To test this hypothesis, we developed a model in which Abcc6(-/-) mice, which recapitulate features of PXE, were fed a diet supplemented with warfarin and vitamin K1. Warfarin action was confirmed by significantly increased serum levels of oxidized vitamin K. For mice placed on a warfarin-containing diet, quantitative chemical and morphometric analyses revealed massive accumulation of mineral deposits in a number of tissues. Mice fed a warfarin-containing diet were also shown to have abundant uncarboxylated form of matrix Gla protein, which allowed progressive tissue mineralization to ensue. To explore the clinical relevance of these findings, 1747 patients with PXE from the approximately 4000 patients in the PXE International database were surveyed about the use of warfarin. Of the 539 respondents, 2.6% reported past or present use of warfarin. Based on the prevalence of PXE (approximately 1:50,000), thousands of patients with PXE worldwide may be at risk for worsening of PXE as a result of warfarin therapy. Topics: Animals; ATP-Binding Cassette Transporters; Calcification, Physiologic; Calcium; Calcium-Binding Proteins; Dermis; Diet; Dietary Supplements; Disease Models, Animal; Extracellular Matrix Proteins; Humans; Magnesium; Matrix Gla Protein; Mice; Minerals; Multidrug Resistance-Associated Proteins; Organ Specificity; Phosphates; Phosphorus; Pseudoxanthoma Elasticum; Vitamin K; Warfarin; X-Ray Microtomography | 2013 |